Umeå biotech company Lipigon makes research collaboration with AstraZeneca
november 20th, 2014
Lipigon Pharmaceuticals and AstraZeneca enter research collaboration to develop a high throughput assay for the identification of molecules that modulate lipoprotein lipase activity.
Lipoprotein lipase (LPL), a spin out from Umeå University, is a promising target for development of new medicines for dyslipidemia and other cardiometabolic risk markers. Recent evidence from genetic- and population studies strongly suggest a causal association between LPL and cardiovascular disease, providing support for LPL as a therapeutic target.
Under the terms of the agreement, the companies will work together to develop a high throughput assay by employing Lipigon’s screening platform for the identification of small molecules that promote the stabilization of LPL.
- This is an exciting opportunity where a small Swedish biotech company with an innovative approach complements AstraZeneca’s research in Cardiovascular and Metabolic Diseases. Lipigon is internationally recognized for their scientific knowledge and technological know-how in a challenging area. I am particulary pleased to see this collaboration come to fruition as it could help strengthening the Nordic Life Science eco-system and bring the next generation of medicine to patients, says Marcus Schindler, VP, CVMD Innovative Medicines unit, AstraZeneca.
Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of LPL biology. Lipigon is currently focusing on the discovery of small molecule activators of LPL.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.